Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 22;13(2):32.
doi: 10.3390/antib13020032.

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Corrado Zengarini  1   2 , Alba Guglielmo  2   3 , Martina Mussi  1   2 , Giovanna Motta  1   4 , Claudio Agostinelli  1   4 , Elena Sabattini  1   4 , Bianca Maria Piraccini  1   2 , Alessandro Pileri  1   2
Affiliations
Review

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Corrado Zengarini et al. Antibodies (Basel). .

Abstract

The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. Monoclonal antibodies like mogamulizumab effectively bind to CCR4, reducing tumour burden and enhancing patient outcomes by inhibiting the receptor's interaction with ligands, thereby hindering malignant T-cell migration and survival. Combining CCR4 antibodies with chemotherapy, radiation, and other drugs is being explored for synergistic effects. Additionally, small-molecular inhibitors, old pharmacological agents interacting with CCR4, and CAR-T therapies are under investigation. Challenges include drug resistance, off-target effects, and patient selection, addressed through ongoing trials refining protocols and identifying biomarkers. Despite advancements, real-life data for most of the emerging treatments are needed to temper expectations. In conclusion, CCR4-targeted therapies show promise for CTCL management, but challenges persist. Continued research aims to optimise treatments, enhance outcomes, and transform CTCL management. This review aims to elucidate the biological rationale and the several agents under various stages of development and clinical evaluation with the actual known data.

Keywords: CCR4; CTCL; chemokine; cutaneous; inflammatory; lymphoma; mediators; oncology; protein; skin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic representation of the molecular pathways activated by CXCR4.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Willemze R., Cerroni L., Kempf W., Berti E., Facchetti F., Swerdlow S.H., Jaffe E.S. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–1714. doi: 10.1182/blood-2018-11-881268. - DOI - PMC - PubMed
    1. Dai J., Duvic M. Cutaneous T-Cell Lymphoma: Current and Emerging Therapies. Oncology. 2023;37:55–62. doi: 10.46883/2023.25920984. - DOI - PubMed
    1. Pileri A., Patrizi A., Agostinelli C., Neri I., Sabattini E., Bacci F., Piccaluga P.P., Pimpinelli N., Pileri S.A. Primary cutaneous lymphomas: A reprisal. Semin. Diagn. Pathol. 2011;28:214–233. doi: 10.1053/j.semdp.2011.04.002. - DOI - PubMed
    1. Pileri A., Morsia E., Zengarini C., Torre E., Goteri G., Quaglino P., Pimpinelli N., Paulli M., Pileri S.A., Zinzani P.L., et al. Epidemiology of cutaneous T-cell lymphomas: State of the art and a focus on the Italian Marche region. Eur. J. Dermatol. 2023;33:360–367. doi: 10.1684/ejd.2023.4531. - DOI - PubMed
    1. Latzka J. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome—Update 2023. Eur. J. Cancer. 2023;195:113343. doi: 10.1016/j.ejca.2023.113343. - DOI - PubMed

LinkOut - more resources